Arbutus Biopharma (NASDAQ:ABUS) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Monday.
ABUS has been the topic of several other reports. Zacks Investment Research cut shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Thursday, January 18th. BidaskClub upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, February 10th. Wedbush cut shares of Arbutus Biopharma from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $9.00 to $6.00 in a report on Monday, March 19th. Finally, Chardan Capital reaffirmed a “buy” rating on shares of Arbutus Biopharma in a research report on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company’s stock. Arbutus Biopharma has an average rating of “Hold” and an average price target of $12.38.
Arbutus Biopharma stock traded up $0.15 during midday trading on Monday, hitting $5.15. 213,618 shares of the stock were exchanged, compared to its average volume of 183,744. Arbutus Biopharma has a 52-week low of $2.95 and a 52-week high of $8.25. The stock has a market cap of $275.35, a PE ratio of -2.88 and a beta of 1.06. The company has a debt-to-equity ratio of 0.09, a quick ratio of 8.85 and a current ratio of 8.85.
Hedge funds have recently made changes to their positions in the business. Point72 Asset Management L.P. bought a new stake in Arbutus Biopharma in the third quarter worth about $1,393,000. RTW Investments LP raised its position in Arbutus Biopharma by 1.1% in the third quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock worth $32,651,000 after acquiring an additional 56,457 shares during the period. Victory Capital Management Inc. raised its position in Arbutus Biopharma by 16.6% in the fourth quarter. Victory Capital Management Inc. now owns 150,720 shares of the biopharmaceutical company’s stock worth $761,000 after acquiring an additional 21,460 shares during the period. Hudson Bay Capital Management LP raised its position in Arbutus Biopharma by 239.0% in the fourth quarter. Hudson Bay Capital Management LP now owns 400,000 shares of the biopharmaceutical company’s stock worth $2,020,000 after acquiring an additional 282,000 shares during the period. Finally, OxFORD Asset Management LLP raised its position in Arbutus Biopharma by 49.2% in the third quarter. OxFORD Asset Management LLP now owns 124,273 shares of the biopharmaceutical company’s stock worth $778,000 after acquiring an additional 40,963 shares during the period. 62.12% of the stock is currently owned by institutional investors and hedge funds.
Arbutus Biopharma Company Profile
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.